Limits...
Serum Golgi protein 73 (GP73) is a diagnostic and prognostic marker of chronic HBV liver disease.

Xu Z, Liu L, Pan X, Wei K, Wei M, Liu L, Yang H, Liu Q - Medicine (Baltimore) (2015)

Bottom Line: In patients with normal ALT levels, serum GP73 concentrations were significantly higher in patients with prominent hepatic inflammatory injury and fibrosis than in patients without hepatic inflammatory injury or fibrosis.Serum GP73 concentrations and GP73 protein expression were decreased in the liver tissues of patients whose ALT levels normalized after 1 year of ETV antiviral therapy.Changes in serum GP73 levels were closely associated with changes in liver injury severity, and, therefore, GP73 may be an effective new liver inflammatory injury biomarker, and could be useful for monitoring the prognosis of chronic HBV infectious patients with normal ALT levels.

View Article: PubMed Central - PubMed

Affiliation: From the Clinical Liver Center (ZX, Liguan Liu, XP, HY, QL); Central Laboratory of Clinical Hepatology (KW, MW); and Department of Pathology (Lifei Liu), The 180th Hospital of the People's Liberation Army, Quanzhou, China.

ABSTRACT
Alanine aminotransferase (ALT) is the most commonly used marker of liver injury, but normal ALT levels are seen in a proportion of chronic hepatitis B virus (HBV)-infected patients with severe liver injury. Golgi protein 73 (GP73) is a promising alternative marker of liver injury. This study assessed the relation between GP73 levels and liver disease severity, monitored the kinetic changes in GP73 levels in chronic HBV patients receiving entecavir (ETV) therapy, and investigated the potential diagnostic and prognostic values of serum GP73 as a new liver injury biomarker in chronic HBV infections. This study enrolled 1150 patients with chronic HBV infections, 200 of whom were retrospectively enrolled in this study after receiving 1 year of ETV treatment. GP73 expression in liver tissue was detected by immunohistochemistry. GP73 levels in single or serial serum samples were measured by enzyme-linked immunosorbent assay. Immunohistochemical analysis indicated that GP73 protein expression in the liver increased progressively with pathologic progression from nonexistent or mild hepatitis to severe hepatitis and cirrhosis during chronic HBV infection. Serum GP73 levels were positively correlated with the disease severity of chronic HBV infections (r = 0.58, P < 0.001). In patients with normal ALT levels, serum GP73 concentrations were significantly higher in patients with prominent hepatic inflammatory injury and fibrosis than in patients without hepatic inflammatory injury or fibrosis. Serum GP73 concentrations and GP73 protein expression were decreased in the liver tissues of patients whose ALT levels normalized after 1 year of ETV antiviral therapy. Changes in serum GP73 levels were closely associated with changes in liver injury severity, and, therefore, GP73 may be an effective new liver inflammatory injury biomarker, and could be useful for monitoring the prognosis of chronic HBV infectious patients with normal ALT levels.

Show MeSH

Related in: MedlinePlus

Serum GP73 level correlated with hepatic necroinflammatory grade (G) and hepatic fibrosis stage (S) in patients with HBV-C. HBV-C = HBV carriers.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4554005&req=5

Figure 4: Serum GP73 level correlated with hepatic necroinflammatory grade (G) and hepatic fibrosis stage (S) in patients with HBV-C. HBV-C = HBV carriers.

Mentions: One-hundred HBV-C patients underwent liver biopsy. Liver pathology scores are shown in Figure 4. We examined the correlation between serum GP73 levels and the extent of pathologic changes, and found that, with the exception of the S3–S4 group, mean serum GP73 concentrations increased significantly with increasing hepatic necroinflammatory grades (G0–G4) and hepatic fibrosis stages (S0–S4) (Figure 4A and B). Serum GP73 levels positively correlated with hepatic necroinflammatory grades (r = 0.55, P < 0.001) and hepatic fibrosis stages (r = 0.53, P < 0.001). Out of 100 cases diagnosed as HBV-C with normal ALT, 29 (29%) and 33 (33%) showed prominent necroinflammation (≥G2) and fibrosis (≥S2), respectively. Serum GP73 levels in patients with pathologic grades ≥G2 and ≥S2 were significantly higher than the serum levels of patients with (G0–G1, or no visible necroinflammation) and (S0–S1, or no visible fibrosis) (all P < 0.001, Table 3). Serum GP73, ALB, TBIL, and ALT levels in 100 HBV-C cases with normal ALT were subjected to multivariate regression analysis. Only serum GP73 was identified as an independent factor for predicting hepatic inflammation (Wald = 16.33, P < 0.001) and fibrosis (Wald = 20.57, P < 0.001). Our data suggest that serum GP73 was a more sensitive liver injury biomarker than ALT, and that its expression also reflected the occurrence of hepatic fibrosis in the patients with HBV-C.


Serum Golgi protein 73 (GP73) is a diagnostic and prognostic marker of chronic HBV liver disease.

Xu Z, Liu L, Pan X, Wei K, Wei M, Liu L, Yang H, Liu Q - Medicine (Baltimore) (2015)

Serum GP73 level correlated with hepatic necroinflammatory grade (G) and hepatic fibrosis stage (S) in patients with HBV-C. HBV-C = HBV carriers.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4554005&req=5

Figure 4: Serum GP73 level correlated with hepatic necroinflammatory grade (G) and hepatic fibrosis stage (S) in patients with HBV-C. HBV-C = HBV carriers.
Mentions: One-hundred HBV-C patients underwent liver biopsy. Liver pathology scores are shown in Figure 4. We examined the correlation between serum GP73 levels and the extent of pathologic changes, and found that, with the exception of the S3–S4 group, mean serum GP73 concentrations increased significantly with increasing hepatic necroinflammatory grades (G0–G4) and hepatic fibrosis stages (S0–S4) (Figure 4A and B). Serum GP73 levels positively correlated with hepatic necroinflammatory grades (r = 0.55, P < 0.001) and hepatic fibrosis stages (r = 0.53, P < 0.001). Out of 100 cases diagnosed as HBV-C with normal ALT, 29 (29%) and 33 (33%) showed prominent necroinflammation (≥G2) and fibrosis (≥S2), respectively. Serum GP73 levels in patients with pathologic grades ≥G2 and ≥S2 were significantly higher than the serum levels of patients with (G0–G1, or no visible necroinflammation) and (S0–S1, or no visible fibrosis) (all P < 0.001, Table 3). Serum GP73, ALB, TBIL, and ALT levels in 100 HBV-C cases with normal ALT were subjected to multivariate regression analysis. Only serum GP73 was identified as an independent factor for predicting hepatic inflammation (Wald = 16.33, P < 0.001) and fibrosis (Wald = 20.57, P < 0.001). Our data suggest that serum GP73 was a more sensitive liver injury biomarker than ALT, and that its expression also reflected the occurrence of hepatic fibrosis in the patients with HBV-C.

Bottom Line: In patients with normal ALT levels, serum GP73 concentrations were significantly higher in patients with prominent hepatic inflammatory injury and fibrosis than in patients without hepatic inflammatory injury or fibrosis.Serum GP73 concentrations and GP73 protein expression were decreased in the liver tissues of patients whose ALT levels normalized after 1 year of ETV antiviral therapy.Changes in serum GP73 levels were closely associated with changes in liver injury severity, and, therefore, GP73 may be an effective new liver inflammatory injury biomarker, and could be useful for monitoring the prognosis of chronic HBV infectious patients with normal ALT levels.

View Article: PubMed Central - PubMed

Affiliation: From the Clinical Liver Center (ZX, Liguan Liu, XP, HY, QL); Central Laboratory of Clinical Hepatology (KW, MW); and Department of Pathology (Lifei Liu), The 180th Hospital of the People's Liberation Army, Quanzhou, China.

ABSTRACT
Alanine aminotransferase (ALT) is the most commonly used marker of liver injury, but normal ALT levels are seen in a proportion of chronic hepatitis B virus (HBV)-infected patients with severe liver injury. Golgi protein 73 (GP73) is a promising alternative marker of liver injury. This study assessed the relation between GP73 levels and liver disease severity, monitored the kinetic changes in GP73 levels in chronic HBV patients receiving entecavir (ETV) therapy, and investigated the potential diagnostic and prognostic values of serum GP73 as a new liver injury biomarker in chronic HBV infections. This study enrolled 1150 patients with chronic HBV infections, 200 of whom were retrospectively enrolled in this study after receiving 1 year of ETV treatment. GP73 expression in liver tissue was detected by immunohistochemistry. GP73 levels in single or serial serum samples were measured by enzyme-linked immunosorbent assay. Immunohistochemical analysis indicated that GP73 protein expression in the liver increased progressively with pathologic progression from nonexistent or mild hepatitis to severe hepatitis and cirrhosis during chronic HBV infection. Serum GP73 levels were positively correlated with the disease severity of chronic HBV infections (r = 0.58, P < 0.001). In patients with normal ALT levels, serum GP73 concentrations were significantly higher in patients with prominent hepatic inflammatory injury and fibrosis than in patients without hepatic inflammatory injury or fibrosis. Serum GP73 concentrations and GP73 protein expression were decreased in the liver tissues of patients whose ALT levels normalized after 1 year of ETV antiviral therapy. Changes in serum GP73 levels were closely associated with changes in liver injury severity, and, therefore, GP73 may be an effective new liver inflammatory injury biomarker, and could be useful for monitoring the prognosis of chronic HBV infectious patients with normal ALT levels.

Show MeSH
Related in: MedlinePlus